Full-Time
Digital Business Partner
Zoetis Services
10,001+ employees
Develops, manufactures, and sells animal vaccines
No salary listed
H1B Sponsorship Available
Kalamazoo, MI, USA
In Person
Travel up to approximately 5% may be required.
Bachelor's, Master's, MBA
 Business & Strategy (1) |
|---|
Get referred to Zoetis Services
See people who can refer or advise you
- A bachelor's degree in Business, Information Systems, Computer Science, Engineering, Genetics, or a related field, or equivalent experience, is required.
- At least 10 years of experience in technology or digital portfolio leadership, information technology business partnership, product management, consulting, or an equivalent area is required.
- At least 5 years of experience leading enterprise or global technology portfolios, products, or transformation programs with accountability for prioritization, investment decisions, and measurable business outcomes is required.
- Demonstrated success with executive stakeholder management, value storytelling, and outcomes measurement using key performance indicators and objectives and key results is required.
- Experience building business cases and leading benefits realization and adoption is required.
- Experience leading cross-functional delivery through influence or matrix leadership is required.
- Demonstrated capability in portfolio shaping, roadmap prioritization, and demand management is required.
- Experience with business-case development, baselining, key performance indicator and objectives-and-key-results definition, and benefits tracking is required.
- Experience with change adoption, stakeholder engagement, and executive-ready communication is required.
- Experience with matrix leadership and delivery governance, including intent, acceptance criteria, and dependency management, is required.
- Experience with forecasting, budget management, and vendor spend management is required.
- A working understanding of data and analytics and digital product delivery fundamentals is required.
- Own the value narrative and outcomes for executive leaders across the data and digital portfolio by clarifying the rationale, defining measurable outcomes, and reporting progress and value realized.
- Translate strategy into an outcomes-based portfolio and roadmap by shaping demand into a prioritized plan that balances run and operate work, regulatory commitments, technical debt, and innovation.
- Build measurable business cases with baselines by quantifying current-state performance, cost, and risk; defining target key performance indicators and objectives and key results; and tracking benefits realization through adoption.
- Drive value realization using PAH domain knowledge and artificial intelligence, large language model, and emerging technologies by identifying and maturing high-impact opportunities from concept to scaled capability.
- Ensure solutions scale as reusable capabilities by promoting platform evolution and build-once patterns, managing dependencies, and avoiding enterprise duplication.
- Champion end-user adoption by ensuring change readiness, training and support alignment, and sustained usage to realize intended outcomes.
- Provide matrix leadership to globally distributed technologists by aligning priorities, clarifying intent and acceptance criteria, removing blockers, and ensuring delivery achieves intended business outcomes.
- Lead and develop Business Partner talent by coaching performance, strengthening consultative partnering, and improving executive communication.
- Operate with financial and execution discipline by managing forecasts and budgets, surfacing tradeoffs early, and escalating risks with concise executive-ready updates.
- Manage software spend and vendor performance while evaluating capability fit and driving sourcing decisions that balance value, risk, and total cost of ownership.
- Plan and execute application and platform lifecycle strategies, including upgrades, modernization, deprecation, and retirement, to keep systems supported, compliant, and sustainable.
- Own vulnerability posture reporting and remediation execution by prioritizing fixes by risk and ensuring issues are tracked to verified closure.
- Lead VDT operational delivery and team performance across incident, problem, and change management; operating model; metrics; and continuous improvement.
- Govern license provisioning and compliance by managing allocations, reclaiming unused entitlements, supporting renewals and audits, and optimizing utilization.
- Own end-to-end reliability and day-to-day operations for VMRD Edge sites by coordinating changes, monitoring, incident response, and stakeholder alignment to protect scientific operations.
- Govern and optimize the application and software portfolio by maintaining inventory, rationalizing redundancy, setting standards, and reporting portfolio health, risk, and value.
- Lead portfolio intake and prioritization, manage cross-project dependencies and capacity, and provide governance and executive reporting across initiatives.
- An advanced degree, such as a Master of Business Administration or Master of Science, is preferred.
- Experience driving artificial-intelligence and large-language-model-enabled capabilities from concept to scaled adoption with appropriate controls is preferred.
- Familiarity with platform thinking and reusable capability design, including build-once patterns, is preferred.
- Knowledge of service management and operational metrics for run and operate is preferred.
- Experience in commercial organization environments and/or exposure to the genetics domain is preferred.
- Experience leveraging shared services, such as GBS or India, and vendors to scale delivery is preferred.
Zoetis creates medicines and vaccines to protect the health of companion animals and livestock. Its products include vaccines, anti-infectives, parasiticides, dermatology and other therapeutics, medicated feed additives, and diagnostics, sold through veterinarians, livestock producers, and pet owners. The company reaches customers in more than 100 countries and relies on big R&D and a global marketing network to bring new solutions to market. Its goal is to improve animal health worldwide by delivering science-based products and services that help care for animals and prevent disease.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parsippany-Troy Hills, New Jersey
Founded
1952
Get referred to Zoetis Services
See people who can refer or advise you
Simplify's Take
What believers are saying
- Portela in Canada and the EU expands Zoetis' chronic-pain franchise beyond Solensia.
- International revenue rose 6% in Q2 2026, offsetting U.S. companion-animal softness.
- Livestock revenue rose 11% in Q2 2026, and diagnostics grew 12% despite market weakness.
What critics are saying
- Zoetis cut 2026 revenue guidance to $9.12-$9.32 billion after Q2 2026 weakness.
- U.S. companion-animal revenue fell 7% in Q2 2026 as Elanco and Merck pressured pricing.
- If clinic visits stay weak through 2027, Zoetis loses share and valuation rerates lower.
What makes Zoetis Services unique
- Zoetis launched Portela in July 2026, first three-month feline osteoarthritis antibody.
- Zoetis owns broad global animal-health scale across 100 countries and two resilient end markets.
- Zoetis combines veterinary science, biologics, and manufacturing control under Jay Saccaro since August 17.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 15%1 year growth
↑ 15%2 year growth
↑ 15%Zoetis, an animal health company, has drawn attention from investor Michael Burry, who is long the stock according to Substack disclosures cited by media outlets. The shares have fallen roughly 40% this year and over 70% from their 2021 peak. Competition from Elanco and Merck in dermatology and parasite treatments has pressured results. In fiscal Q2 2026, revenue was roughly flat, with US sales down 7% whilst international revenue grew 6%. The stock now trades near 12 times forward earnings, compared with a historical average of 30 times. Zoetis maintains around 86% of the US pet skin drug market, with gross margins above 70%. Wall Street analysts remain mostly bullish, with consensus price targets suggesting roughly 70% upside potential.
Zoetis reported flat revenue of $2.47 billion in Q2, missing Wall Street estimates of $2.50 billion, though adjusted earnings per share of $1.87 slightly beat consensus. The animal health company faces intensifying competition in key Companion Animal categories and declining US veterinary clinic visits. CEO Kristin Peck noted that veterinary visits have declined across markets for multiple years, coinciding with price increases exceeding broader consumer inflation. The company's Livestock and Diagnostics segments showed resilience despite weakness in dermatology and parasiticides. Zoetis lowered its full-year revenue guidance to $9.22 billion from $9.82 billion, a 6.1% reduction, and cut adjusted EPS guidance to $6.20, down 10.5%. Operating margin fell to 37.4% from 39.1% year-on-year. Management indicated it is implementing temporary, targeted promotional actions rather than permanent price cuts to defend market share. Competitive pressures may persist into 2027.
Zoetis has appointed former GE Healthcare CFO Jay Saccaro to a newly created dual role as CFO and chief operating officer, effective 17 August. Saccaro, who spent three years at GE Healthcare and nine years as CFO at Baxter International Healthcare, will receive an annual base salary of $1 million, with eligibility for bonuses totalling 100% of his salary and long-term incentives worth $5 million. He will also receive a one-time restricted stock unit award valued at approximately $6.2 million and a cash award of $1.2 million. Current CFO Wetteny Joseph will transition to special advisor on 16 August, remaining in a non-executive role until February 2027 or an earlier agreed date. The appointment comes as the New Jersey-based animal health company seeks new growth opportunities amid economic headwinds.
Zoetis reported second-quarter 2026 adjusted earnings of $1.87 per share, beating the consensus estimate of $1.84. However, total revenues of $2.47 billion fell flat year over year and marginally missed expectations of $2.49 billion. US segment revenues declined 7% to $1.30 billion, driven by an 11% drop in companion animal product sales due to softer demand and increased competition. Livestock product sales in the US rose 23% to $222 million. International segment revenues increased 8% to $1.17 billion, supported by growth in parasiticides and livestock products. Zoetis cut its 2026 revenue guidance to $9.12-9.32 billion, reflecting expected operational growth of negative 1-3%. Year to date, shares have plunged 40%.
Zoetis reported Q2 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis. Adjusted diluted earnings per share rose 4% to $1.87, whilst adjusted net income fell 2% to $781 million. The animal health company's global companion animal revenue declined 6% to $1.7 billion, with key dermatology products down 16% to $395 million. However, livestock revenue grew 11% to $731 million, driven by demand in cattle and poultry. International markets provided growth momentum, with revenue up 6% to $1.2 billion, whilst US revenue fell 7% to $1.3 billion. Companion animal diagnostics revenue increased 12% to $118 million. For full-year 2026, Zoetis expects revenue of $9.12 billion to $9.32 billion and adjusted diluted EPS of $6.15 to $6.25.